Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And lastly, we continue to retain a strong cash position to fund our operations well through the end of 2025 |
| We are also very pleased to see our proprietary portfolio of ANKET progressing |
| Altogether, these elements result in a differentiated making for ADC showing strong efficacy in preclinical models, including in fact set by factory PDX as well as encouraging PK tox profile in the non-human primates |
| And the global overall response rate was an encouraging 37.5% |
| We are excited about our prospects for the future |
| The thinking here is that the dual targeting of the PD-L1 and the NKG2A pathways through this combination will lead to enhanced antitumor activity versus single-agent therapy |
| It's great to see the progress along and the expanding of the portfolio |
| Our agreement with Takeda in the field provides the validation to this research approach and highlights our capability to generate differentiated ADC candidates |
| We remain, however, committed to the PTCL through the Phase 2 study in combination with chemotherapy, where we expect to see some synergism between lacutamab and chemotherapy and therefore, provide some meaningful clinical benefit to patients |
| So just to conclude, over the years, we have established a strong expertise in immunopharmacology with definitive Phase 2 data in hand, we are mapping out the regulatory next steps for lacutamab |
| Second, we continue to fuel our innovative portfolio with both ANKET on antibody drug conjugates |
| In this dose escalation, we were encouraged to see initial preliminary single agent activity and safety of SAR’579 in relapsed recurrent AML patients |
| And I wish you a very good day, and looking forward to the next steps |
| Top SAR'579 was well tolerated up to 6 mg/kg with no dose-limiting toxicity observed and only 2 grade 1 CRS observed out of 43 patients |
| As we continue to develop next generation therapeutics having single agent activity utilizing our antibody-engineering platform, we find that for some tumor targets we can generate antibodies with good internalizing property that therefore are well suited for ADC development |
| Frederic Lombard, our CFO, will cover the financials, and we're very pleased to welcome Arvind Sood, EVP, U.S |
| We and then expanded, post Sezary syndrome to mycosis fungoides where we have seen encouraging preliminary data from the Phase 2 TELLOMAK trial in patients that have a KIR3DL2 expression level above as well as below the threshold of 1% |
| A favorable safety profile was also observed, and we look forward to sharing this data set along with the final data in the causes from world's code with the regulator, later on |
| As you can see, our pipeline of ANKET molecule is significantly growing with Sanofi having now licensed 4 molecules |
| Finally, we selected a well validated Topo I inhibitor with bystander effect, allowing to bypass MMAE related resistance mechanism and to address tumors with pathogenicity making for expression |
| Now that we have the data in MF and these data are -- and this data are this preliminary -- this data are promising |
| We were pleased to announce earlier this month that IPH65, the first of the second-generation aggregates, which target CD20 has entered the clinic, and the first in human has started with the first patient being dosed in March |
| And before I close, I would also like to thank the many employees at Innate, who work very hard in developing therapies for the potential benefit of patients |
| Eventually this is through partnership, we have monalizumab or checkpoint inhibitor in Phase 3 on AstraZeneca is pursuing this late-stage asset which will deliver in the next year very important data |
| The second generation ANKET IPH6501 is now in the clinic and we continue to fuel our pipeline with new preclinical program against multiple targets |
| Good morning and good afternoon, everyone |
| Now the data in MF together with the data in excess will be shared with regulators to align on a path forward to maximize the value of lacutamab in CTCL building on the existing fast track and orphan designation |
| However, based on the data presented at ASH last year demonstrating the synergies between lacutamab and chemotherapy preclinical models of PTCL, we remain committed to the development on PTCL and continue to enroll patients in the Phase 2 combination trial with chemotherapy, gemcitabine and oxaliplatin, where we believe the combination can offer additional benefit to patient |
| Slide 13 highlights our growing antibody drug conjugate pipeline |
| Leveraging our scientific expertise in the antisense space, this platform is an enzyme for producing series of drug candidates addressing multiple tumor targets, both in heme and solid tumors |
| Statement |
|---|
| I apologize did our presenters go on mute? Ladies and gentlemen, we are experiencing technical difficulties |
| Now, the IPH65 pro forma also addresses the commentary and associated with the loss of CD16 by ensuring activation of intratumoral NK cells via the activation of NKp46 |
| Ladies and gentlemen, thank you for your patience, while we managed our technical difficulties |
| As the number of observed objective responses did not meet the pre-specified threshold for activity with lacutamab as a single agent |
| General and administrative expenses amounted to EUR18.3 million, down by 18.5% on prior year due to the decrease in personnel expenses, non-scientific advisory fees and other expenses, mainly resulting from efficiency measures applied by the company |
Please consider a small donation if you think this website provides you with relevant information